首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNa |
| Uniprot No | P01562 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-189aa |
| 氨基酸序列 | M+CDLPETHSL DNRRTLMLLA QMSRISPSSC LMDRHDFGFP QEEFDGNQFQ KAPAISVLHE LIQQIFNLFT TKDSSAAWDE DLLDKFCTEL YQQLNDLEAC VMQEERVGET PLMNVDSILA VKKYFRRITL YLTEKKYSPC AWEVVRAEIM RSLSLSTNLQ ERLRRKE |
| 预测分子量 | 19.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于IFNα重组蛋白的参考文献示例(内容为模拟概括，具体文献需核实)：
---
1. **文献名称**：*"Peginterferon alfa-2a alone or in combination with ribavirin for chronic hepatitis C virus infection"*
**作者**：Fried MW, et al.
**摘要**：研究聚乙二醇化重组IFNα-2a(PEG-IFNα)单用或联合利巴韦林治疗慢性丙型肝炎的疗效，证明其可显著提高持续病毒学应答率，成为丙肝标准治疗方案之一。
2. **文献名称**：*"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma"*
**作者**：Kirkwood JM, et al.
**摘要**：探讨重组IFNα-2b作为黑色素瘤术后辅助治疗的临床效果，证实高剂量IFNα可延长无复发生存期，但伴随明显副作用。
3. **文献名称**：*"Structural basis of receptor binding and activation of human IFNα"*
**作者**：Jaitin DA, et al.
**摘要**：通过X射线晶体学解析重组人IFNα蛋白与其受体的结合结构，揭示其激活JAK-STAT信号通路的关键表位，为优化重组IFNα药物提供理论依据。
---
如需具体文献，建议通过PubMed或Web of Science以关键词“recombinant IFNα”、“pegylated interferon”等检索近年高被引论文。
Interferon-alpha (IFNα) is a member of the type I interferon family, a group of naturally occurring cytokines pivotal in innate immunity. First identified in the 1950s for their ability to "interfere" with viral replication, IFNs are now recognized for their broad regulatory roles in immune responses, cell proliferation, and apoptosis. IFNα is primarily produced by plasmacytoid dendritic cells and leukocytes in response to viral infections or tumorigenic signals. It exerts biological effects by binding to a heterodimeric receptor complex (IFNAR1/IFNAR2), activating the JAK-STAT signaling pathway, which induces the expression of interferon-stimulated genes (ISGs) with antiviral, antiproliferative, and immunomodulatory functions.
Recombinant IFNα proteins, developed in the 1980s using genetic engineering techniques, revolutionized therapeutic applications. Early versions were produced in *E. coli* through recombinant DNA technology, enabling large-scale production of highly pure, bioactive IFNα. Later, mammalian cell expression systems improved post-translational modifications, enhancing stability and efficacy. Clinically, recombinant IFNα has been widely used to treat chronic hepatitis B/C, certain cancers (e.g., hairy cell leukemia, melanoma), and multiple sclerosis. However, its use is limited by side effects (e.g., flu-like symptoms, neurotoxicity) and short plasma half-life, prompting innovations like pegylation (PEG-IFNα) to prolong activity.
Current research focuses on optimizing IFNα delivery, exploring combination therapies with checkpoint inhibitors, and elucidating its role in modulating tumor microenvironments. As a cornerstone of cytokine-based therapeutics, recombinant IFNα remains a critical tool for understanding host-pathogen interactions and developing targeted immunotherapies.
×
